Combined drug and CRISPR/CAS9 screening reveals specific targets for SF3B1- and NOTCH1- mutated CLL cells.

Warning

This publication doesn't include Faculty of Sports Studies. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.

Authors	DOSTÁLOVÁ Lenka LADUNGOVÁ Adriana ŠKRNOVÁ Dominika GOTTUMUKKALA Narendra Varma LODHI Yusuf ŠMÍDA Michal
Year of publication	2022
Type	Conference abstract
MU Faculty or unit	Central European Institute of Technology
Citation	DOSTÁLOVÁ, Lenka; Adriana LADUNGOVÁ; Dominika ŠKRNOVÁ; Narendra Varma GOTTUMUKKALA; Yusuf LODHI and Michal ŠMÍDA. Combined drug and CRISPR/CAS9 screening reveals specific targets for SF3B1- and NOTCH1- mutated CLL cells. In EHA 2022 in HemaSphere 2022; 6(S3): 1012-1013. 2022.
Related projects:	Genome-wide CRISPR/Cas9 screening to identify novel therapeutical targets for NOTCH1 and SF3B1 mutated B-cell chronic lymphocytic leukemia Specifický výzkum v oblasti „Life Sciences“ Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit IX